stockrowElanco Animal Health Incorporated
ELAN Healthcare Drug Manufacturers Specialty & Generic
Elanco Animal Health Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 6.22% from fiscal 2024.
- Revenue
- +10.2%
- EPS
- +450.0%
- Free cash flow
- +35.6%
- Total debt
- −6.91%
Quarter to June 2026, against a year earlier
Follow ELAN
Alert me
Elanco Animal Health Incorporated (ELAN) Revenue growth
Elanco Animal Health Incorporated's revenue growth over the twelve months to 30 June 2026 was 12.0%, up 5.7 percentage points from fiscal 2025 (6.22%). Over the past ten years it has ranged from −7.41% (fiscal 2022) to 45.6% (fiscal 2021); the current reading is higher than 82% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 5.22% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 6.22% | 5.72 |
| FY2024 | 0.50% | 0.36 |
| FY2023 | 0.14% | 7.55 |
| FY2022 | −7.41% | (53.05) |
| FY2021 | 45.6% | 39.13 |
| FY2020 | 6.51% | 6.37 |
| FY2019 | 0.14% | (6.01) |
| FY2018 | 6.15% | 6.99 |
| FY2017 | −0.84% | (0.99) |
| FY2016 | 0.15% | 0.30 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | 10.2% | (4.69) |
| Mar 2026 | 14.9% | 2.76 |
| Dec 2025 | 12.2% | 1.77 |
| Sep 2025 | 10.4% | 5.58 |
| 31 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| KNSA Kiniksa Pharmaceuticals International, plc compare | 58.2% |
| NBIX Neurocrine Biosciences, Inc. compare | 38.0% |
| HIMS Hims & Hers Health, Inc. compare | 28.0% |
| ALKS Alkermes plc compare | 15.3% |
| ELAN Elanco Animal Health Incorporated | 12.0% |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | 8.88% |
| VTRS Viatris Inc. compare | 4.27% |
| LNTH Lantheus Holdings, Inc. compare | 2.38% |
| RDY Dr. Reddy's Laboratories Ltd compare | −15.5% |
| Drug Manufacturers Specialty & Generic industry median | 5.22% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on ELAN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement